Histological transformation into pulmonary sarcomatoid carcinoma from lung adenosquamous carcinoma after radical resection of EGFR gene Exon-21 L858R mutation: a case report and literature review - Report - MDSpire
Advertisement
Histological transformation into pulmonary sarcomatoid carcinoma from lung adenosquamous carcinoma after radical resection of EGFR gene Exon-21 L858R mutation: a case report and literature review
Clinical Report: Histological Progression from Lung Adenosquamous Carcinoma
Overview
Revise to accurately reflect the progression from adenosquamous carcinoma to PSC and the implications of the EGFR mutation.
Background
Pulmonary sarcomatoid carcinoma (PSC) is a rare and aggressive form of non-small cell lung cancer (NSCLC), often characterized by poor prognosis and resistance to standard therapies. Its histological features can lead to misdiagnosis, complicating treatment strategies. Understanding the progression from other lung cancer types to PSC is crucial for improving clinical outcomes.
Data Highlights
No numerical data provided in the article.
Key Findings
PSC is frequently underdiagnosed due to its rarity and complex histology.
Histological transformation from adenosquamous carcinoma to PSC can occur following EGFR-TKI treatment.
The patient achieved a durable complete response to combined immunochemotherapy after recurrence.
High PD-L1 expression in PSC suggests potential responsiveness to immune checkpoint inhibitors.
No consensus guidelines exist for the management of PSC, necessitating extrapolation from NSCLC protocols.
Clinical Implications
Clinicians should be aware of the potential for histological transformation in lung cancer patients treated with EGFR-TKIs. The favorable response to immunotherapy in PSC patients with high PD-L1 expression may guide treatment decisions in similar cases.
Conclusion
This case underscores the need for heightened awareness of PSC and the importance of tailored treatment approaches following histological transformation in lung cancer.
